288 completed. 288 Phase 1, 34 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 288 | Completed 288 |
| Phase 2 | 34 | Completed 34 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bioequivalence Study to Compare Brexpiprazole 4 mg Film Coated Tablets Versus RXULTI 4 mg Film Coated Tablet (Brexpiprazole) Brexpiprazole Film Coated Tablets, RXULTI film coated tablet - Schizophrenia | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2025-06-22 | 2025-12-05 |
| The Combination of Pharmacotherapy and Cognitive Behavioral Psychotherapy Under the Recovery Perspective. Group A. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by anxiety disorders and depression., Group B. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by PTSD, Group C. The combination of pharmacotherapy and individual cognitive behavioral psychotherapy by obsessive-compulsive disorder. - Anxiety, Depression | Phase 1 | Completed | Rakitzi, Stavroula | 107 | 2025-06-02 | 2026-08-04 |
| A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women SEP-380135, Quinidine Gluconate - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | 2025-03-07 | 2026-01-15 |
| A Study of SEP-380135 in Adults With Schizophrenia or Major Depressive Episode SEP-380135, Placebo - Schizophrenia, Major Depressive Disorder (MDD) | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 43 | 2024-11-07 | 2026-04-24 |
| Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder Lumateperone Capsule, Lumateperone LAI - Schizophrenia or Schizoaffective | Phase 1 | Completed | Intra-Cellular Therapies, Inc. | 52 | 2024-08-23 | 2026-07-31 |
| A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects LY03020, Placebo - Schizophrenia, Alzheimer's Disease Psychosis | Phase 1 | Completed | Luye Pharma Group Ltd. | 66 | 2024-08-19 | 2025-05-29 |
| Bioequivalence Assessment Between Two Cariprazine Hard Capsule Formulations Test Product (Vocarzine), Reference (R) Reagila ® - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Aya Mohammed Abdel Magid Abdel Hamid | 29 | 2024-08-03 | 2025-08-17 |
| Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions VHX-896 and iloperidone, Iloperidone and VHX-896 - Schizophrenia, Bipolar I Disorder | Phase 1 | Completed | Vanda Pharmaceuticals | 26 | 2024-07-11 | 2025-09-19 |
| Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder Olanzapine Extended Release, Olanzapine Immediate Release - Schizophrenia, Schizoaffective Disorder | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 106 | 2024-03-28 | 2026-01-26 |
| Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia TV-44749 318mg, Oral Olanzapine 10mg/day, TV-44749 425mg - Schizophrenia | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 24 | 2024-03-28 | 2026-06-30 |
| An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia TV-44749, Oral olanzapine - Schizophrenia | Phase 1 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 153 | 2024-03-20 | 2026-01-14 |
| A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years KYN-5356, placebo - Cognitive Dysfunction, Schizophrenia | Phase 1 | Completed | Kynexis B.V. | 72 | 2023-12-21 | 2024-12-04 |
| Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia OPC-34712FUM/ Brexpiprazole fumarate - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Co., Ltd. | 59 | 2023-10-03 | 2026-02-11 |
| Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal - Schizophrenia | Phase 1 | Completed | Rovi Pharmaceuticals Laboratories | 58 | 2023-09-26 | 2025-09-08 |
| A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001) MK-5720, Placebo to MK-5720, MK-8189 - Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 17 | 2023-09-15 | 2025-03-04 |
| A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019) Elpipodect, Moxifloxacin, Placebo - Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 107 | 2023-06-26 | 2026-04-29 |
| A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia SEP-363856, Placebo - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 60 | 2023-06-21 | 2024-06-26 |
| A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 19 | 2022-11-15 | 2024-06-26 |
| A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia SEP-363856 - Schizophrenia | Phase 1 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 15 | 2022-08-30 | 2024-06-26 |
| A Study of Elpipodect (MK-8189) in Participants With Schizophrenia (MK-8189-014) Elpipodect, Placebo - Schizophrenia | Phase 1 | Completed | Merck Sharp & Dohme LLC | 53 | 2022-07-12 | 2026-04-29 |
Showing 20 of 288. Sign in to see all of them.
Psychotic Disorders (60) · Mood Disorders (23) · Bipolar Disorder (11) · Mental Disorders (7) · Cognitive Dysfunction (5) · Alzheimer Disease (3) · Schizophrenia Spectrum and Other Psychotic Disorders (3) · Anxiety Disorders (2) · Depression (2) · Depressive Disorder (2) · Depressive Disorder, Major (2) · Obesity (2) · Psychomotor Agitation (2) · Renal Insufficiency (2)
Schizophrenia Spectrum and Other Psychotic Disorders (285) · Mental Disorders (281) · Nervous System Diseases (12) · Bipolar and Related Disorders (11) · Mood Disorders (11) · Pathological Conditions, Signs and Symptoms (9) · Signs and Symptoms (9) · Neurocognitive Disorders (8) · Neurologic Manifestations (8) · Behavior (6) · Central Nervous System Diseases (6) · Chemically-Induced Disorders (5) · Cognition Disorders (5) · Neurobehavioral Manifestations (5) · Behavioral Symptoms (4)
Paliperidone Palmitate (21) · Risperidone (18) · Aripiprazole (16) · Olanzapine (14) · SEP-363856 (12) · Lurasidone Hydrochloride (8) · Ketamine (6) · MK-8189 (6) · Quetiapine Fumarate (6) · Moxifloxacin (5) · PF-04958242 (5) · iloperidone (5) · Transcranial Direct Current Stimulation (4) · Acetylcysteine (3) · Clozapine (3)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (31) · Otsuka Pharmaceutical Development & Commercialization, Inc. (27) · GlaxoSmithKline (13) · Pfizer (8) · Luye Pharma Group Ltd. (7) · Merck Sharp & Dohme LLC (7) · Yale University (7) · Sumitomo Pharma America, Inc. (6) · Wyeth is now a wholly owned subsidiary of Pfizer (6) · Biogen (5) · H. Lundbeck A/S (5) · Hoffmann-La Roche (5) · Alkermes, Inc. (4) · Autifony Therapeutics Limited (4) · Cerevel Therapeutics, LLC (4)
United States (170) · United Kingdom (23) · Spain (9) · China (8) · Japan (7) · Germany (6) · Belgium (5) · Croatia (5) · South Korea (5) · Australia (4) · Canada (4) · Brazil (3) · Israel (3) · Pakistan (3) · Slovakia (3)
ChaoYing Hu, MD (2) · For-Wey Lung, MD, ScD (2)
PMID 38244179, PMID 22992330, PMID 28204607, PMID 28350572, PMID 28695535, PMID 32141724, PMID 41034820, PMID 18227146, PMID 18626272, PMID 19915181, PMID 20537128, PMID 20537130, PMID 20584515, PMID 22160487, PMID 22383949, PMID 22452559, PMID 22455454, PMID 22513041, PMID 22717030, PMID 23822566, PMID 24419307, PMID 24423017, PMID 25563714, PMID 25693889, PMID 25735992, PMID 26072311, PMID 26116126, PMID 26306819, PMID 26631428, PMID 26911397, PMID 27089154, PMID 27136907, PMID 27333588, PMID 27371157, PMID 27617637, PMID 27655012, PMID 27743205, PMID 27871302, PMID 28318835, PMID 28597226, PMID 28845238, PMID 28965778, PMID 29103081, PMID 29177699, PMID 30348514, PMID 30509308, PMID 30536081, PMID 30599145, PMID 31236286, PMID 31264510
2008 (1), 2014 (1), 2016 (1), 2017 (1), 2019 (1), 2023 (1), I01CX001414 (1), K23DA018203 (1), R01DA013196 (1), R01DA026799 (1), R01DA034699 (1), R01MH059101 (1), R01MH060390 (1), R01MH061412 (1), R01MH068725 (1)